Article thumbnail

Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab

By Manuel Valladares Ayerbes, Rafael López López and Mercedes Salgado Fernández
Publisher: 'Oxford University Press (OUP)'
Year: 2015
DOI identifier: 10.1093/annonc/mdv233.269
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.